Table 3.

Baseline values and corresponding changes after 4-week treatment period in women

Parameter	Baseline values			Change to Week 4
	Treamid	Placebo	p-valuea	Treamid	Placebo	Treamid superiority	p-valuea
Borg scale (score)	n = 19	n = 14		n = 19	n = 14
	2.2 ± 0.9	2.1 ± 1.1	0.748 (w)	− 1.2 ± 0.5	− 0.5 ± 0.9	0.7	0.010* (u)
	2.0 (2.0; 3.0)	2.0 (1.0; 2.9)		− 1.0 (− 1.5; − 1.0)	− 0.5 (− 1.0; 0.0)	0.5	0.005* (m); 0.208 (mr)
6MWD (% pred.)	n = 19	n = 14		n = 19	n = 14
	81.3 ± 15.3	80.9 ± 16.2	0.952 (t)	22.4 ± 23.7	15.5 ± 11.0	6.9%	0.815 (u)
	84.6 (76.0; 90.1)	80.4 (74.3; 92.1)		13.4 (6.7; 28.3)	14.3 (7.3; 19.7)	− 0.9%	0.883 (m); 0.993 (mr)
TLC (% pred.)	n = 19	n = 14		n = 18	n = 14
	94.6 ± 14.1	102.6 ± 16.9	0.117 (w)	8.1 ± 10.5	− 0.9 ± 5.3	9.0%	0.004* (t)
	90.0 (84.8; 105.0)	98.1 (91.5; 105.6)		7.6 (− 0.7; 13.7)	− 1.3 (− 5.1; 1.7)	8.9%	0.035* (m); 0.049* (mr)
FVC (% pred.)	n = 19	n = 14		n = 19	n = 14
	85.1 ± 13.8	81.0 ± 9.9	0.502 (w)	3.3 ± 9.3	3.6 ± 6.4	− 0.3%	0.901 (t)
	79.0 (75.0; 89.8)	78.0 (75.0; 88.3)		4.7 (− 2.4; 9.2)	1.7 (0.0; 6.2)	3%	0.355 (m); 0.436 (mr)
DLCO (% pred.)	n = 19	n = 14		n = 18	n = 14
	73.2 ± 17.3	72.6 ± 12.9	0.536 (w)	10.6 ± 12.6	9.5 ± 17.7	1.1%	0.595 (u)
	66.0 (61.6; 77.6)	72.2 (64.9; 78.8)		10.3 (− 0.7; 20.0)	5.5 (− 0.9; 13.7)	4.8%	0.483 (m); 0.437 (mr)
Lung damage (%)	n = 19	n = 14		n = 19	n = 13
	27.5 ± 21.5	27.4 ± 24.7	0.739 (w)	− 17.1 ± 11.7	− 10.5 ± 12.6	6.6%	0.073 (u)
	25.0 (9.0; 49.0)	24.5 (5.0; 46.2)		− 15.0 (− 25.0; − 6.5)	− 5.0 (− 24.0; 0.0)	10.0%	0.039* (m); 0.073 (mr)

Baseline values and change in parameters for women (М ± SD and median (Q1; Q3))

Data in bold indicates significant p-value (< 0.05) according to at least one of the tests used

^aTest is put in brackets: m—median test, mr—median regression, t—Student’s t-test, u—Mann–Whitney test